It's never too early to think commercial. Many of the decisions that determine patient access are made years before launch. Here's why commercialization starts in development, not after approval.
The biggest commercialization decision isn't pricing or market access, it's modality. The choices made years before launch ultimately determine which patients a therapy can realistically reach.
Commercial lag is one of the most expensive hidden problems in life sciences companies. Learn why commercial success in CGT requires both deal execution and market positioning — and why one commercial hire is often not enough.
In today’s Cell and Gene Therapy market, scientific differentiation alone is no longer enough. Learn why CGT companies must build commercial authority early — and how positioning, visibility, and market trust drive long-term commercial success.